Topical Cyclosporine (Restasis, Cequa) for chronic allergic conjunctivitis

Type: drug

Status: Off-label use, growing evidence

Developer: Allergan (now AbbVie)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026